1. Home
  2. GGR vs CGTX Comparison

GGR vs CGTX Comparison

Compare GGR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$4.35

Market Cap

82.9M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.12

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
CGTX
Founded
2011
2007
Country
Taiwan
United States
Employees
1416
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.9M
94.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GGR
CGTX
Price
$4.35
$1.12
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
5.9K
1.5M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.22
52 Week High
$6.21
$3.83

Technical Indicators

Market Signals
Indicator
GGR
CGTX
Relative Strength Index (RSI) 65.32 57.81
Support Level $3.63 $1.01
Resistance Level $4.25 $1.19
Average True Range (ATR) 0.21 0.10
MACD 0.03 0.04
Stochastic Oscillator 81.17 88.43

Price Performance

Historical Comparison
GGR
CGTX

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: